Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -17.50 -5.47% 302.50 295.00 310.00 305.00 295.00 305.00 64,002 08:39:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.2 -26.2 - 142

Faron Pharmaceuticals Oy Exercise of options

24/09/2020 7:15am

UK Regulatory (RNS & others)


Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart


From Aug 2020 to Oct 2020

Click Here for more Faron Pharmaceuticals Oy Charts.

TIDMFARN

RNS Number : 9411Z

Faron Pharmaceuticals Oy

24 September 2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Exercise of options

Issue of equity

Company announcement, 24 September 2020 at 9.15 (EEST)

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that it has received notifications from option holders to exercise D options over 15,000 ordinary shares in the Company at an exercise price of EUR 1.09 (approx. GBP 1.00) per share under the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and conditions of the 2015 Option Plan are available on the Company's website at https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf .

Applications will be made to the London Stock Exchange and Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM and Nasdaq First North Growth Market, respectively. Admission of the New Ordinary Shares is expected to occur on or around 5 October 2020 following issue and registration of the New Ordinary Shares on or around 2 October 2020 ("Registration"). The New Ordinary Shares will rank pari passu with existing ordinary shares.

Faron's enlarged issued number of shares immediately following Registration will be 46,814,747 ordinary shares with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, Registration, the total number of voting rights in Faron will be 46,814,747. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the issued shares and votes of the Company.

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner, Mark Rogers

Phone: +44 207 213 0880

Panmure Gordon (UK) Limited, Broker

Rupert Dearden

Phone: +44 207 886 2500

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen, Jussi Majamaa

Phone: +358 (0)40 555 4727

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

Email: faron@consilium-comms.com

Stern Investor Relations, Inc.

Julie Seidel, Naina Zaman

Phone: +1 (212) 362-1200

Email: faron@sternir.com

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen(R), its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen(R) has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine(R), the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine(R). Faron is based in Turku, Finland. Further information is available at www.faron.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEDBGDCLXDDGGX

(END) Dow Jones Newswires

September 24, 2020 02:15 ET (06:15 GMT)

1 Year Faron Pharmaceuticals Oy Chart

1 Year Faron Pharmaceuticals Oy Chart

1 Month Faron Pharmaceuticals Oy Chart

1 Month Faron Pharmaceuticals Oy Chart
ADVFN Advertorial
Your Recent History
LSE
FARN
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201025 14:48:03